In response to the COVID-19 pandemic, HRSA’s Office of Pharmacy Affairs has made a number of adjustments to its guidelines for the 340B drug pricing program for stakeholders.

We take a deeper dive into the moves pharma has been making and the executive order affecting FQHCs that we mentioned in previous blogs last month, discuss the long-awaited court decision about the Medicare part B reimbursement cuts, and we also take a look at HRSA’s new registration and recertification requirements.

Our new Foundations Certificate program is a method of training that is interactive and application based—meaning the training provides scenarios to support optimal use of all of Sentry’s tools in a peer setting.

For almost 30 years, the 340B program has proven to be dynamic and versatile. It has adapted to the changing healthcare landscape before and will do so again.

There’s no understating the impact that delayed or denied claims can have on your organization’s bottom line – particularly claims in which clinicians at hospitals and health systems administer medication as part of the treatment plan.

On Friday, June 24, President Trump signed four executive orders aimed at lowering the high cost of drugs in the US.

This month, we bring you a bonus 340Buzz report in addition to our monthly blog post. Three pharma companies have attempted to stir the pot when it comes to what’s within their rights regarding the 340B program. Merck and Sanofi release manufacturer…

This month, HHS distributes $4 billion in additional relief to safety-net hospitals, AHA loses the price transparency rule legal battle, and a new Senate bill aims to protect 340B eligibility during COVID-19. Price transparency moves ahead In…

Federally Qualified Health Centers (FQHCs) operate on a not-for-profit basis and serve a disproportionate share of our nation’s vulnerable population – patients who often struggle with interconnected disparities that affect their health,…